Disease relevance of RPL19

• High-level expression of the ribosomal protein L19 in human breast tumors that overexpress erbB-2 [1].
• Analysis of RPL19 mRNA expression by in situ hybridization revealed a significant increase of RPL19 expression in a substantial number of prostate cancers [2].
• Gleason scores of the carcinomas correlated with RPL19 expression (chi(2): n = 87, P < 0.001) [2].

High impact information on RPL19

• Human cDNAs encoding elongation factor 1 gamma and the ribosomal protein L19 [3].
• Northern blot hybridization analysis done on a wide range of human cell lines and tissues confirmed the level of RPL19 mRNA to be 5-fold higher in malignant cell lines and 8-fold higher in malignant tissues, when compared with their benign counterparts [2].
• Microquantity differential display analysis of gene expression profiles between benign (PNT2) and malignant (PC3M) human prostate cell lines identified the gene encoding ribosomal protein L19 (RPL19) to be overexpressed in the malignant cells [2].
• Analysis of a 17.4 kb DNA segment of yeast chromosome II encompassing the ribosomal protein L19 as well as proteins with homologies to components of the hnRNP and snRNP complexes and to the human proliferation-associated p120 antigen [4].

References